Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPH-104 in Recurrent Pericarditis
NCT05107934Phase 3Suspended
- Sponsor
- R-Pharm
- Start
- Dec 2025
- Primary completion
- May 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of goflikicept in recurrent pericarditis, sponsored by R-Pharm. Started Dec 2025; status: suspended.
02
Drugs
goflikicept
03
Conditions
recurrent pericarditis
Beyond the preview
Go deeper on NCT05107934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107934.